Cross-source evidence timeline

Lanreotide research timeline

Follow 68 selected, directly cited source records from August 30, 2007 through June 27, 2026. This timeline joins source lanes for navigation; it does not infer that one record confirms another.

68Selected records
14Source years
4Evidence lanes
June 27, 2026Latest source date

Source year

2026

14 records
Literature metadata · 7Clinical trials · 4Safety · 3
  1. Literature metadata

    PubMed record PMID 41880072

    PeptideScanner retained PubMed bibliographic metadata for PMID 41880072 at 2026-07-30T16:14:14.928Z. PubMed recorded a metadata revision date of 2026-06-27 and an Entrez history date of 2026-03-25. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date.

  2. Literature metadata

    PubMed record PMID 39933708

    PeptideScanner retained PubMed bibliographic metadata for PMID 39933708 at 2026-07-30T16:14:10.854Z. PubMed recorded a metadata revision date of 2026-06-09 and an Entrez history date of 2025-02-11. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date.

  3. Literature metadata

    PubMed record PMID 38071418

    PeptideScanner retained PubMed bibliographic metadata for PMID 38071418 at 2026-07-30T16:20:36.586Z. PubMed recorded a metadata revision date of 2026-05-18 and an Entrez history date of 2023-12-10. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date.

  4. Literature metadata

    β-Cyclodextrin derivatives bind aromatic side chains of the cyclic peptide lanreotide.

    PubMed lists PMID 39491674 in Journal of pharmaceutical sciences as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-11-02 (day precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

  5. Literature metadata

    Combined Lanreotide Autogel and Temozolomide Treatment of Progressive Pancreatic and Intestinal Neuroendocrine Tumors: The Phase II SONNET Study.

    PubMed lists PMID 38206830 in The oncologist as Journal Article, Clinical Trial, Phase II, Research Support, Non-U.S. Gov't, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2024-05-03 (day precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

  6. Safety

    FDA enforcement report D-0422-2026

    FDA's dated enforcement report D-0422-2026 lists Class II and source status Ongoing for Cipla USA, Inc. PeptideScanner connects the report to reviewed application NDA215395 through exact openFDA application-number annotations.

  7. Safety

    FDA enforcement report D-0423-2026

    FDA's dated enforcement report D-0423-2026 lists Class II and source status Ongoing for Cipla USA, Inc. PeptideScanner connects the report to reviewed application ANDA217193 through exact openFDA application-number annotations.

  8. Clinical trials

    ClinicalTrials.gov record NCT05048901

    PeptideScanner retained ClinicalTrials.gov record NCT05048901 at 2026-07-30T16:20:49.324Z. Its registry update date was 2026-04-09, and PeptideScanner's reviewed identity mapping was lanreotide.

  9. Clinical trials

    ClinicalTrials.gov record NCT02127437

    PeptideScanner retained ClinicalTrials.gov record NCT02127437 at 2026-07-30T16:20:49.305Z. Its registry update date was 2026-04-08, and PeptideScanner's reviewed identity mapping was lanreotide.

  10. Clinical trials

    ClinicalTrials.gov record NCT06807437

    PeptideScanner retained ClinicalTrials.gov record NCT06807437 at 2026-07-30T16:22:22.334Z. Its registry update date was 2026-03-31, and PeptideScanner's reviewed identity mapping was lanreotide.

  11. Literature metadata

    Lanreotide in endothelial corneal inflammation.

    PubMed lists PMID 41071230 in Hormones (Athens, Greece) as Letter, with publication-date metadata of 2025-10-10 (day precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

  12. Clinical trials

    ClinicalTrials.gov record NCT03946527

    PeptideScanner retained ClinicalTrials.gov record NCT03946527 at 2026-07-30T16:22:22.335Z. Its registry update date was 2026-03-02, and PeptideScanner's reviewed identity mapping was lanreotide.

  13. Literature metadata

    Four-year follow-up of acromegalic patients treated with the new long-acting formulation of Lanreotide (Lanreotide Autogel).

    PubMed lists PMID 15789272 in Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association as Journal Article, with publication-date metadata of 2005-03 (month precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

  14. Safety

    FDA enforcement report D-0290-2026

    FDA's dated enforcement report D-0290-2026 lists Class II and source status Ongoing for Cipla USA, Inc. PeptideScanner connects the report to reviewed application NDA215395 through exact openFDA application-number annotations.

Source year

2025

1 record
Regulatory · 1
  1. Regulatory

    Lanreotide DailyMed SPL version 3

    DailyMed lists Structured Product Labeling version 3 for the reviewed Lanreotide label family with a published date of 2025-06-02. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

Source year

2024

3 records
Regulatory · 3
  1. Regulatory

    Lanreotide DailyMed SPL version 2

    DailyMed lists Structured Product Labeling version 2 for the reviewed Lanreotide label family with a published date of 2024-12-02. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

  2. Regulatory

    Lanreotide DailyMed SPL version 1

    DailyMed lists Structured Product Labeling version 1 for the reviewed Lanreotide label family with a published date of 2024-05-23. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

  3. Regulatory

    Drugs@FDA application ANDA217193

    The official Drugs@FDA dataset lists original submission 1 for ANDA 217193 with status AP dated 2024-05-21, and names lanreotide acetate among the application record's active ingredients.

Source year

2023

1 record
Clinical trials · 1
  1. Clinical trials

    ClinicalTrials.gov record NCT03043664

    PeptideScanner retained ClinicalTrials.gov record NCT03043664 at 2026-07-30T19:11:49.726Z. Its registry update date was 2023-06-29, and PeptideScanner's reviewed identity mapping was lanreotide.

Source year

2022

2 records
Clinical trials · 2
  1. Clinical trials

    ClinicalTrials.gov record NCT00774930

    PeptideScanner retained ClinicalTrials.gov record NCT00774930 at 2026-07-30T19:34:18.792Z. Its registry update date was 2022-10-14, and PeptideScanner's reviewed identity mapping was lanreotide.

  2. Clinical trials

    ClinicalTrials.gov record NCT03158090

    PeptideScanner retained ClinicalTrials.gov record NCT03158090 at 2026-07-30T19:42:14.203Z. Its registry update date was 2022-03-16, and PeptideScanner's reviewed identity mapping was lanreotide.

Source year

2021

2 records
Clinical trials · 1Regulatory · 1
  1. Regulatory

    Drugs@FDA application NDA215395

    The official Drugs@FDA dataset lists original submission 1 for NDA 215395 with status AP dated 2021-12-17, and names lanreotide acetate among the application record's active ingredients.

  2. Clinical trials

    ClinicalTrials.gov record NCT03012594

    PeptideScanner retained ClinicalTrials.gov record NCT03012594 at 2026-07-30T20:07:13.495Z. Its registry update date was 2021-01-15, and PeptideScanner's reviewed identity mapping was lanreotide.

Source year

2019

1 record
Clinical trials · 1
  1. Clinical trials

    ClinicalTrials.gov record NCT02075606

    PeptideScanner retained ClinicalTrials.gov record NCT02075606 at 2026-07-30T20:50:35.870Z. Its registry update date was 2019-06-07, and PeptideScanner's reviewed identity mapping was lanreotide.

Source year

2017

1 record
Clinical trials · 1
  1. Clinical trials

    ClinicalTrials.gov record NCT02351128

    PeptideScanner retained ClinicalTrials.gov record NCT02351128 at 2026-07-30T21:22:00.252Z. Its registry update date was 2017-10-18, and PeptideScanner's reviewed identity mapping was lanreotide.

Source year

2016

36 records
Literature metadata · 36
  1. Literature metadata

    [Treatment of acromegaly with sustained-release lanreotide. A new somatostatin analog].

    PubMed lists PMID 8099735 in Presse medicale (Paris, France : 1983) as Journal Article, with publication-date metadata of 1993-03-27 (day precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

  2. Literature metadata

    Combinative treatment of transarterial chemoembolization, celecoxib and lanreotide in unresectable hepatocellular carcinoma.

    PubMed lists PMID 25746137 in Clinics and research in hepatology and gastroenterology as Case Reports, Letter, Research Support, Non-U.S. Gov't, with publication-date metadata of 2015-03-04 (day precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

  3. Literature metadata

    Long-acting lanreotide in adolescent girls with constitutional tall stature.

    PubMed lists PMID 19258715 in Hormone research as Clinical Trial, Journal Article, Multicenter Study, with publication-date metadata of 2009-03-04 (day precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

  4. Literature metadata

    Preliminary experience with (68)Ga-DOTA-lanreotide positron emission tomography.

    PubMed lists PMID 20168286 in The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of... as Clinical Trial, Journal Article, with publication-date metadata of 2010-02 (month precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

  5. Literature metadata

    Elucidation of the self-assembly pathway of lanreotide octapeptide into beta-sheet nanotubes: role of two stable intermediates.

    PubMed lists PMID 20199027 in Journal of the American Chemical Society as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2010-03-31 (day precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

  6. Literature metadata

    Therapeutic 188Re-lanreotide: determination of radiopharmacokinetic parameters in rats.

    PubMed lists PMID 20604834 in The Journal of pharmacy and pharmacology as Journal Article, with publication-date metadata of 2010-04 (month precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

  7. Literature metadata

    Use of lanreotide for the treatment of gastrointestinal fistulae.

    PubMed lists PMID 21135689 in Annals of surgery as Letter, Comment, with publication-date metadata of 2011-01 (month precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

  8. Literature metadata

    Resolving bile reflux by lanreotide in patients with Roux-en-Y gastrojejunostomy.

    PubMed lists PMID 25682623 in Acta gastro-enterologica Belgica as Case Reports, Journal Article, with publication-date metadata of 2014-12 (month precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

  9. Literature metadata

    [Somatuline(R) Autogel(R), a new formulation of lanreotide for the treatment of acromegalic patients].

    PubMed lists PMID 12037499 in Annales d'endocrinologie as Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2002-04 (month precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

  10. Literature metadata

    [Lanreotide in the treatment of thyroid orbitopathy].

    PubMed lists PMID 15789913 in Przeglad lekarski as Journal Article, with publication-date metadata of 2004 (year precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

  11. Literature metadata

    Pharmacokinetics and population pharmacodynamic analysis of lanreotide Autogel.

    PubMed lists PMID 16154424 in Metabolism: clinical and experimental as Clinical Trial, Clinical Trial, Phase III, Journal Article, Multicenter Study, with publication-date metadata of 2005-10 (month precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

  12. Literature metadata

    Radiation recall dermatitis in a patient affected with pheochromocytoma after treatment with lanreotide.

    PubMed lists PMID 17854356 in The British journal of dermatology as Case Reports, Letter, with publication-date metadata of 2007-09-13 (day precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

  13. Literature metadata

    Self-assembly of the octapeptide lanreotide and lanreotide-based derivatives: the role of the aromatic residues.

    PubMed lists PMID 17929329 in Journal of peptide science : an official publication of the European Peptide Society as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2008-01 (month precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

  14. Literature metadata

    Optimalization and cost management of lanreotide-Autogel therapy in acromegaly.

    PubMed lists PMID 17984236 in European journal of endocrinology as Comparative Study, Journal Article, Multicenter Study, with publication-date metadata of 2007-11 (month precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

  15. Literature metadata

    Lanreotide autogel and insulin sensitivity markers: report of 5 acromegalic patients and literature review.

    PubMed lists PMID 18063933 in Neuro endocrinology letters as Clinical Trial, Journal Article, Review, with publication-date metadata of 2007-12 (month precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

  16. Literature metadata

    Lanreotide Autogel for persistent diabetic macular edema.

    PubMed lists PMID 18367285 in Diabetes research and clinical practice as Case Reports, Journal Article, with publication-date metadata of 2008-03-26 (day precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

  17. Literature metadata

    Para-aortic lymphocele treated with an injection of somatostatine analog (lanreotide).

    PubMed lists PMID 18684551 in European journal of obstetrics, gynecology, and reproductive biology as Case Reports, Letter, with publication-date metadata of 2008-08-05 (day precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

  18. Literature metadata

    PubMed record PMID 10199803

    PeptideScanner retained PubMed bibliographic metadata for PMID 10199803 at 2026-07-30T21:35:52.336Z. PubMed recorded a metadata revision date of 2016-11-24 and an Entrez history date of 1999-04-13. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date.

  19. Literature metadata

    PubMed record PMID 10231313

    PeptideScanner retained PubMed bibliographic metadata for PMID 10231313 at 2026-07-30T21:35:52.337Z. PubMed recorded a metadata revision date of 2016-11-24 and an Entrez history date of 1999-05-07. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date.

  20. Literature metadata

    PubMed record PMID 10480146

    PeptideScanner retained PubMed bibliographic metadata for PMID 10480146 at 2026-07-30T21:35:52.338Z. PubMed recorded a metadata revision date of 2016-11-24 and an Entrez history date of 1999-09-10. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date.

  21. Literature metadata

    PubMed record PMID 10579475

    PeptideScanner retained PubMed bibliographic metadata for PMID 10579475 at 2026-07-30T21:35:52.340Z. PubMed recorded a metadata revision date of 2016-11-24 and an Entrez history date of 1999-12-01. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date.

  22. Literature metadata

    PubMed record PMID 10748802

    PeptideScanner retained PubMed bibliographic metadata for PMID 10748802 at 2026-07-30T21:35:52.342Z. PubMed recorded a metadata revision date of 2016-11-24 and an Entrez history date of 2000-04-05. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date.

  23. Literature metadata

    PubMed record PMID 11095353

    PeptideScanner retained PubMed bibliographic metadata for PMID 11095353 at 2026-07-30T21:35:52.345Z. PubMed recorded a metadata revision date of 2016-11-24 and an Entrez history date of 2000-11-30. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date.

  24. Literature metadata

    PubMed record PMID 11128563

    PeptideScanner retained PubMed bibliographic metadata for PMID 11128563 at 2026-07-30T21:35:52.346Z. PubMed recorded a metadata revision date of 2016-11-24 and an Entrez history date of 2000-12-29. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date.

  25. Literature metadata

    PubMed record PMID 8954072

    PeptideScanner retained PubMed bibliographic metadata for PMID 8954072 at 2026-07-30T21:35:51.206Z. PubMed recorded a metadata revision date of 2016-11-24 and an Entrez history date of 1996-12-01. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date.

  26. Literature metadata

    PubMed record PMID 9119171

    PeptideScanner retained PubMed bibliographic metadata for PMID 9119171 at 2026-07-30T21:35:52.319Z. PubMed recorded a metadata revision date of 2016-11-24 and an Entrez history date of 1996-01-01. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date.

  27. Literature metadata

    PubMed record PMID 9537429

    PeptideScanner retained PubMed bibliographic metadata for PMID 9537429 at 2026-07-30T21:35:52.324Z. PubMed recorded a metadata revision date of 2016-11-24 and an Entrez history date of 1998-04-16. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date.

  28. Literature metadata

    PubMed record PMID 9867148

    PeptideScanner retained PubMed bibliographic metadata for PMID 9867148 at 2026-07-30T21:35:52.335Z. PubMed recorded a metadata revision date of 2016-11-24 and an Entrez history date of 1998-12-29. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date.

  29. Literature metadata

    PubMed record PMID 9934776

    PeptideScanner retained PubMed bibliographic metadata for PMID 9934776 at 2026-07-30T21:35:52.335Z. PubMed recorded a metadata revision date of 2016-11-24 and an Entrez history date of 1999-02-06. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date.

  30. Literature metadata

    PubMed record PMID 8975096

    PeptideScanner retained PubMed bibliographic metadata for PMID 8975096 at 2026-07-30T21:35:51.206Z. PubMed recorded a metadata revision date of 2016-11-23 and an Entrez history date of 1996-09-07. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date.

  31. Literature metadata

    PubMed record PMID 7864583

    PeptideScanner retained PubMed bibliographic metadata for PMID 7864583 at 2026-07-30T21:35:51.193Z. PubMed recorded a metadata revision date of 2016-11-23 and an Entrez history date of 1994-01-01. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date.

  32. Literature metadata

    PubMed record PMID 8646723

    PeptideScanner retained PubMed bibliographic metadata for PMID 8646723 at 2026-07-30T21:35:51.201Z. PubMed recorded a metadata revision date of 2016-11-23 and an Entrez history date of 1996-07-01. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date.

  33. Literature metadata

    PubMed record PMID 8786564

    PeptideScanner retained PubMed bibliographic metadata for PMID 8786564 at 2026-07-30T21:35:51.203Z. PubMed recorded a metadata revision date of 2016-11-23 and an Entrez history date of 1996-03-01. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date.

  34. Literature metadata

    PubMed record PMID 8931985

    PeptideScanner retained PubMed bibliographic metadata for PMID 8931985 at 2026-07-30T21:35:51.205Z. PubMed recorded a metadata revision date of 2016-11-23 and an Entrez history date of 1996-09-01. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date.

  35. Literature metadata

    PubMed record PMID 7540120

    PeptideScanner retained PubMed bibliographic metadata for PMID 7540120 at 2026-07-30T21:35:51.187Z. PubMed recorded a metadata revision date of 2016-11-23 and an Entrez history date of 1995-01-01. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date.

  36. Literature metadata

    PubMed record PMID 27200668

    PeptideScanner retained PubMed bibliographic metadata for PMID 27200668 at 2026-07-30T21:38:23.145Z. PubMed recorded a metadata revision date of 2016-05-21 and an Entrez history date of 2016-05-21. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date.

Source year

2014

3 records
Clinical trials · 1Literature metadata · 1Regulatory · 1
  1. Literature metadata

    PubMed record PMID 15003204

    PeptideScanner retained PubMed bibliographic metadata for PMID 15003204 at 2026-07-30T21:55:37.950Z. PubMed recorded a metadata revision date of 2014-08-18 and an Entrez history date of 2004-03-09. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date.

  2. Regulatory

    Federal Register notice 2014-17293

    The Federal Register published notice 2014-17293, attributed to FDA and its parent HHS department, on 2014-07-23. Its official title is “Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Lanreotide.

  3. Clinical trials

    ClinicalTrials.gov record NCT01354405

    PeptideScanner retained ClinicalTrials.gov record NCT01354405 at 2026-07-30T21:54:46.540Z. Its registry update date was 2014-07-09, and PeptideScanner's reviewed identity mapping was lanreotide.

Source year

2011

1 record
Literature metadata · 1
  1. Literature metadata

    PubMed record PMID 21607321

    PeptideScanner retained PubMed bibliographic metadata for PMID 21607321 at 2026-07-30T22:17:00.088Z. PubMed recorded a metadata revision date of 2011-05-24 and an Entrez history date of 2011-05-25. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date.

Source year

2009

1 record
Clinical trials · 1
  1. Clinical trials

    ClinicalTrials.gov record NCT00565097

    PeptideScanner retained ClinicalTrials.gov record NCT00565097 at 2026-07-30T22:26:45.013Z. Its registry update date was 2009-02-17, and PeptideScanner's reviewed identity mapping was lanreotide.

Source year

2008

1 record
Regulatory · 1
  1. Regulatory

    Federal Register notice E8-27179

    The Federal Register published notice E8-27179, attributed to FDA and its parent HHS department, on 2008-11-17. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; SOMATULINE DEPOT,” and PeptideScanner's exact reviewed identity mapping connects the document to Lanreotide.

Source year

2007

1 record
Regulatory · 1
  1. Regulatory

    Drugs@FDA application NDA022074

    The official Drugs@FDA dataset lists original submission 1 for NDA 022074 with status AP dated 2007-08-30, and names lanreotide acetate among the application record's active ingredients.